TAKHZYRO 150 mg, solution for injection in a pre-filled syringe syringe, 1 ml
Active ingredients: Lanadelumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionsyringe, 1 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- TAKHZYRO 150 mg, solution injectable en seringue préremplie
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 seringue(s) préremplie(s) en verre de 1 ml
- Marketing authorisation holder
- TAKEDA PHARMACEUTICALS INTERNATIONAL (IRLANDE)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Apr 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67650090CIP73028030CIP133400930280300Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LANADÉLUMABsolution | 150 mg · une seringue préremplie de 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.